Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OBIO vs PTN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Captures Overall Composite Edge (37.5 SELL vs 31.5 SELL), While PTN Leads 4–2 on Growth & Valuation Pillars

OBIO Overall Winner 6-Pillar Tally: OBIO 2 – 4 PTN Matrix Metrics: OBIO 5 – 5 PTN

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (37.5/100 SELL vs. 31.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.12 (N/M Forward P/E, -195.4% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin).

  • Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.5/100 SELL vs. PTN 31.5/100 SELL) and 1.15β · 82% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both OBIO (37.5/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs PTN
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 82% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 69
RSI-14: 69.2 · SMA20: $5.93 · SMA50: $5.90
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07

6-Pillar Scorecard Institutional Category Breakdown (OBIO 2 – 4 PTN)

Columns: Metric · OBIO · PTN
1. Valuation Multiples PTN
Forward P/E N/M 42.9x
Trailing P/E N/M 42.9x
PEG Ratio N/M 1.62x
EV / Revenue 18.6x 0.1x
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% -80.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M $13M
Market Cap $570.6M $11.1M
3. Profitability & Quality PTN
Gross Margin 99.6% 6.2%
Operating Margin -195.4% -65.7%
Net Profit Margin -182.5% -63.5%
Return on Equity (ROE) -182.3% -877.5%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$64M -$15M
Cash Flow Margin N/A -113.6%
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $9.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 70.8% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity N/A 71.9% of Rev ($9.5M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (5) vs PTN (5)
Institutional Metric OBIO PTN Criterion Row Edge
Market Capitalization
Scale
$570.6M $11.1M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Forward P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY)
Growth
-89.4% -80.1% Higher Growth PTN
Operating Margin (TTM)
Profitability
-195.4% -65.7% Higher Margin PTN
Net Profit Margin
Profitability
-182.5% -63.5% Higher Margin PTN
Return on Equity (ROE)
Capital Efficiency
-182.3% -877.5% Higher ROE OBIO
52-Week Range Position
Momentum
92% ($3–$7) 6% ($5–$31) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.15β · 82% Vol 0.87β · 106% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 31.5 / 100 (SELL) Higher Composite OBIO
Trailing 12M Revenue (USD)
Operating Scale
$31M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% 6.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.6x EV/Rev 1.62x PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$15M ($9.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +28.9 pp
OBIO: +30.64% · PTN: +1.74%
3M Horizon OBIO +67.52 pp
OBIO: +25.8% · PTN: -41.72%
6M Horizon OBIO +138.7 pp
OBIO: +78.89% · PTN: -59.81%
1Y Horizon OBIO +113.62 pp
OBIO: +70.33% · PTN: -43.29%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue PTN Revenue OBIO Op. Margin PTN Op. Margin Margin Leader
FY2018 N/A $70M N/A 38.6% PTN
FY2019 N/A $60M N/A 59.3% PTN
FY2020 N/A $0M N/A -20007.6% PTN
FY2022 $0M $0M -924.3% -2491.6% OBIO
FY2023 $0M $0M -1866.2% -668.7% PTN
FY2024 $0M $0M -2437.5% -501.0% PTN
FY2025 $30M N/A -154.7% N/A OBIO
FY2026 N/A $10M N/A -65.7% PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO BREAKOUT
32d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs PTN Key Questions & Quantitative Answers

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (37.5/100 SELL vs. 31.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.12 (N/M Forward P/E, -195.4% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.5/100 SELL vs. PTN 31.5/100 SELL) and 1.15β · 82% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both OBIO (37.5/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), OBIO cumulative revenue shifted N/A while PTN shifted -85.7%. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.

PTN screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus PTN (-877.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.